Combined therapy with PPARα agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency

Objective: Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily and are key regulators of fatty acid oxidation (FAO) in the heart. Systemic carnitine deficiency (SCD) causes disorders of FAO and induces hypertrophic cardiomyopathy with lipid accumulation. We hypothesized that activation of PPAR alpha by fenofibrate, a PPAR alpha agonist, in addition to conventional L-carnitine supplementation may exert beneficial effects on the lipotoxic cardiomyopathy in juvenile visceral steatosis (JVS) mouse, a murine model of SCD. Methods: Both wild-type (WT) and JVS mice were fed a normal chow, 0.2% fenofibrate containing chow (FE), a 0.1% L-carnitine containing chow (CA) or a 0.1% L-carnitine+0.2% fenofibrate containing chow (CA+FE) from 4 weeks of age. Four to 8 animals per group were used for each experiment and 9 to 11 animals per group were used for survival analysis. Results: At 8 weeks of age, JVS mice exhibited marked ventricular hypertrophy, which was more attenuated by CA+FE than by CA or FE alone. CA+FE markedly reduced the high plasma and myocardial triglyceride levels and increased the low myocardial ATP content to control levels in TVs mice. In JVS mice, myocardial 1,2-diacylglycerol (DAG) was significantly increased and showed a distinct fatty acid composition with elevation of 18:1(n-7,9) and 18:2(n-6) fatty acids compared with that in WT mice. CA+FE significantly altered the fatty acid composition of DAG and inhibited the membrane translocation of cardiac protein kinase C beta 2 in JVS mice. Furthermore, CA+FE prevented the progressive left ventricular dysfunction and dramatically improved the survival rate in JVS mice (survival rate at 400 days after birth: 89 vs. 0%, P < 0.0001). Conclusions: PPAR alpha activation, in addition to L-carnitine supplementation, may rescue the detrimental lipotoxic cardiomyopathy in SCD by improving cardiac energy and lipid metabolism as well as systemic lipid metabolism. (c) 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.